IP Library › Granted Patent US 12,479,792
Granted Patent B2
US 12,479,792 · App. 16/336,665 · Granted Nov 25, 2025

Compositions of chelating molecules

Inventors: Rebecca J. Abergel (Oakland, CA); Julian Rees (Oakland, CA); Ilya Captain (Oakland, CA)
Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
C07C235/60A61K38/07A61K38/1709A61K51/0478A61K51/0482C07D213/89C07K5/1008
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,479,792
App. No.
16/336,665
Granted
Nov 25, 2025
Kind
B2
Abstract

Provided herein are a variety of metal chelators as well as methods of use thereof.

Claims (38)

1 . A composition having a structure comprising:

wherein:

(i) A1, A2, A3, and A4, are independently selected from the group consisting of a CAM group, a 1,2-HOPO group, and an HA group, wherein at least one of A1, A2, A3, and A4 is a 1,2-HOPO group, at least one of A1, A2, A3, and A4 is a CAM group, and at least one of A1, A2, A3, and A4 is an HA group;

(ii) B1, B2, B3, and B4, are independently selected from the group consisting of an amide group and an amine group;

(iii) C1, C2, C3, C4, C5, and C6 are conjugation groups, wherein C1-C6 is independently selected from the group consisting of NH 2 , C(═O)OH, maleimide, dibromo-maleimide, isothiocyanate, alkyne, and azide;

(iv) at least another one of C1, C2, C3, C4, C5, or C6 is optional;

(v) L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12, and L13 are linking groups, wherein L1-L13 is independently selected from the group consisting of an alkyl group having 1 to 10 carbon atoms, an alkylamino group having 1 to 10 carbon atoms and 1 to 2 nitrogen atoms; an alkylamido group having 1 to 10 carbon atoms and 1 to 2 nitrogen atoms; an alkyl ether group having 1 to 10 carbon atoms, a hydroxy ester group, or an alkyl ester group having 1 to 10 carbon atoms; and

(vi) at least one of L1, L5, L6, L7, L8, L9, L10, L11, L12, or L13 is optional,

wherein the structure comprises a plurality of metal coordinating atoms, wherein the plurality of metal coordinating atoms is included in the 1,2-HOPO, CAM, and HA groups, wherein the metal coordinating atoms can bond with metals having cations with a +1, +2, +3, and/or +4 charge,

wherein the 1,2-HOPO group is defined by a structure

 and comprises a pyridinone ring substituted by a hydroxyl group on the N atom,

wherein the CAM group is defined by a structure

 and comprises at least a phenyl ring substituted by hydroxyl groups on adjacent carbon atoms,

wherein the HA group is defined by a structure

 wherein R α is H or an alkyl group including no greater than 5 carbon atoms, and

wherein the composition has at least one pharmaceutically acceptable carrier, wherein the at least one pharmaceutical acceptable carrier is selected from the group consisting of absorption delaying agents, antioxidants, binders, buffering agents, bulking agents or fillers, chelating agents, coatings, disintegration agents, dispersion media, gels, isotonic agents, lubricants, preservatives, pharmaceutically acceptable salts, solvents, stabilizers, and surfactants.

2 . A composition of claim 1 , wherein at least another one of L2, L3, or L4, is independently selected from the group consisting of an amine group or an amide group.

3 . A composition of claim 1 , wherein L1, C1, L7, C2, L9, C3, L11, C4, and L13, C5 are absent, L5 consists of an unsubstituted alkyl group having 1 to 5 carbon atoms, and C6 is selected from the group consisting of NH2, C(═O) OH, maleimide, dibromo-maleimide, isothiocyanate, alkyne, and azide.

4 . A composition of claim 3 , wherein L2, L3, L4, L6, L8, L10, and L12, independently, consist of an unsubstituted alkyl group having 1 to 5 carbon atoms.

5 . A composition of claim 4 , wherein A1 consists of a CAM group or a HOPO group; A2 consists of a HA group, A3 consists of a HA group, and A4 consists of a CAM group, a HOPO group, or a HA group.

6 . A composition of claim 1 , wherein at least one of L2, L3, or L4, independently, consists of an alkylamino or alkylamido group.

7 . A composition of claim 1 , wherein B1, B2, and B3, independently, consist of an amide group and B4 consists of an amino group, L2 and L3 consist of an amino group, and L4 consists of an alky group having 1 to 5 carbon atoms.

8 . A composition of claim 7 , wherein:

C1, C2, C3, C4, C5, L1, A1, A2, A3, L1, L6, L7, L8, L9, L10, L11, L12, and L13 are absent,

A4 consists of a CAM group, a HOPO group, or a HA group; and

L5 consists of an alkyl group having 1 to 5 carbon atoms.

9 . A composition of claim 1 , wherein B1, B2, and B3, independently, consist of an amide group and B4 consists of an amide group, L2 and L3, individually, consist of an amino group, and L4 consists of an alky group having 1 to 5 carbon atoms.

10 . A composition of claim 9 , wherein C1, C2, C3, C4, C5, A1, A2, A3, L1, L6, L7, L8, L9, L10, L11, and L13 are absent, L12 consists of an amino group, L5 consists of an ether group having 1 to 10 carbon atoms, and A4 consists of a CAM group, a HOPO group, or a HA group.

11 . A composition of claim 1 , wherein C1, C2, C5, C6, L1, L2, L3, L4, L5, L7, L13, B2, and B4 are absent, B1 and B3, independently, consist of an amide group, L6, L8, L10, and L12, independently, consist of an amino group, A1, A2, A3, and A4, independently, consist of a CAM group, a HOPO group, or a HA group, L9 and L11, independently, consist of an alkyl group having 1 to 5 carbon atoms.

12 . A composition of claim 1 , further comprising a metal, wherein the metal comprises a radionuclide.

13 . A composition of claim 12 , wherein the radionuclide comprises 225 Ac, 226 Ac, 228 Ac, 105 Ag, 106 mAg, 110 mAg, 111 Ag, 112 Ag, 113 Ag, 239 Am, 240 Am, 242 Am, 244 Am, 37 Ar, 71 As, 72 As, 73 As, 74 As, 76 As, 77 As, 209 At, 210 At, 191 Au, 192 Au, 193 Au, 194 Au, 195 Au, 196 Au, 196 m 2 Au, 198 Au, 198 mAu, 199 Au, 200 mAu, 128 Ba, 131 Ba, 133 mBa, 135 mBa, 140 Ba, 7 Be, 203 Bi, 204 Bi, 205 Bi, 206 Bi, 210 Bi, 212 Bi, 243 Bk, 244 Bk, 245 Bk, 246 Bk, 248 mBk, 250 Bk, 76 Br, 77 Br, 80 mBr, 82 Br, 11 C, 14 C, 45 Ca, 47 Ca, 107 Cd, 115 Cd, 115 mCd, 117 mCd, 132 Ce, 133 mCe, 134 Ce, 135 Ce, 137 Ce, 137 mCe, 139 Ce, 141 Ce, 143 Ce, 144 Ce, 246 Cf, 247 Cf, 253 Cf, 254 Cf, 240 Cm, 241 Cm, 242 Cm, 252 Cm, 55 Co, 56 Co, 57 Co, 58 Co, 58 mCo, 60 Co, 48 Cr, 51 Cr, 127 Cs, 129 Cs, 131 Cs, 132 Cs, 136 Cs, 137 Cs, 61 Cu, 62 Cu, 64 Cu, 67 Cu, 153 Dy, 155 Dy, 157 Dy, 159 Dy, 165 Dy, 166 Dy, 160 Er, 161 Er, 165 Er, 169 Er, 171 Er, 172 Er, 250 Es, 251 Es, 253 Es, 254 Es, 254 mEs, 255 Es, 256 mEs, 145 Eu, 146 Eu, 147 Eu, 148 Eu, 149 Eu, 150 mEu, 152 mEu, 156 Eu, 157 Eu, 52 Fe, 59 Fe, 251 Fm, 252 Fm, 253 Fm, 254 Fm, 255 Fm, 257 Fm, 66 Ga, 67 Ga, 68 Ga, 72 Ga, 73 Ga, 146 Gd, 147 Gd, 149 Gd, 151 Gd, 153 Gd, 159 Gd, 68 Ge, 69 Ge, 71 Ge, 77 Ge, 170 Hf, 171 Hf, 173 Hf, 175 Hf, 179 m 2 Hf, 180 mHf, 181 Hf, 184 Hf, 192 Hg, 193 Hg, 193 mHg, 195 Hg, 195 mHg, 197 Hg, 197 mHg, 203 Hg, 160 mHo, 166 Ho, 167 Ho, 123 I, 124 I, 126 I, 130 I, 132 I, 133 I, 135 I, 109 In, 110 In, 111 In, 114 mIn, 115 mIn, 184 Ir, 185 Ir, 186 Ir, 187 Ir, 188 Ir, 189 Ir, 190 Ir, 190 m 2 Ir, 192 Ir, 193 mIr, 194 Ir, 194 m 2 Ir, 195 mIr, 42 K, 43 K, 76 Kr, 79 Kr, 81 mKr, 85 mKr, 132 La, 133 La, 135 La, 140 La, 141 La, 262 Lr, 169 Lu, 170 Lu, 171 Lu, 172 Lu, 174 mLu, 176 mLu, 177 Lu, 177 mLu, 179 Lu, 257 Md, 258 Md, 260 Md, 28 Mg, 52 Mn, 90 Mo, 93 mMo, 99 Mo, 13 N, 24 Na, 90 Nb, 91 mNb, 92 mNb, 95 Nb, 95 mNb, 96 Nb, 138 Nd, 139 mNd, 140 Nd, 147 Nd, 56 Ni, 57 Ni, 66 Ni, 234 Np, 236 mNp, 238 Np, 239 Np, 15 O, 182 Os, 183 Os, 183 mOs, 185 Os, 189 mOs, 191 Os, 191 mOs, 193 Os, 32 P, 33 P, 228 Pa, 229 Pa, 230 Pa, 232 Pa, 233 Pa, 234 Pa, 200 Pb, 201 Pb, 202 mPb, 203 Pb, 209 Pb, 212 Pb, 100 Pd, 101 Pd, 103 Pd, 109 Pd, 111 mPd, 112 Pd, 143 Pm, 148 Pm, 148 mPm, 149 Pm, 151 Pm, 204 Po, 206 Po, 207 Po, 210 Po, 139 Pr, 142 Pr, 143 Pr, 145 Pr, 188 Pt, 189 Pt, 191 Pt, 193 mPt, 195 mPt, 197 Pt, 200 Pt, 202 Pt, 234 Pu, 237 Pu, 243 Pu, 245 Pu, 246 Pu, 247 Pu, 223 Ra, 224 Ra, 225 Ra, 81 Rb, 82 Rb, 82 mRb, 83 Rb, 84 Rb, 86 Rb, 181 Re, 182 Re, 182 mRe, 183 Re, 184 Re, 184 mRe, 186 Re, 188 Re, 189 Re, 190 mRe, 99 Rh, 99 mRh, 100 Rh, 101 mRh, 102 Rh, 103 mRh, 105 Rh, 211 Rn, 222 Rn, 97 Ru, 103 Ru, 105 Ru, 35 S, 118 mSb, 119 Sb, 120 Sb, 120 mSb, 122 Sb, 124 Sb, 126 Sb, 127 Sb, 128 Sb, 129 Sb, 43 Sc, 44 Sc, 44 mSc, 46 Sc, 47 Sc, 48 Sc, 72 Se, 73 Se, 75 Se, 153 Sm, 156 Sm, 110 Sn, 113 Sn, 117 mSn, 119 mSn, 121 Sn, 123 Sn, 125 Sn, 82 Sr, 83 Sr, 85 Sr, 89 Sr, 91 Sr, 173 Ta, 175 Ta, 176 Ta, 177 Ta, 180 Ta, 182 Ta, 183 Ta, 184 Ta, 149 Tb, 150 Tb, 151 Tb, 152 Tb, 153 Tb, 154 Tb, 154 mTb, 154 m 2 Tb, 155 Tb, 156 Tb, 156 mTb, 156 m 2 Tb, 160 Tb, 161 Tb, 94 Tc, 95 Tc, 95 mTc, 96 Tc, 97 mTc, 9 mTc, 118 Te, 119 Te, 119 m Te, 121 Te, 121 mTe, 123 mTe, 125 mTe, 127 Te, 127 m Te, 129 m Te, 131 mTe, 132 Te, 227 Th, 231 Th, 234 Th, 45 Ti, 198 Tl, 199 Tl, 200 Tl, 201 Tl, 202 Tl, 204 Tl, 165 Tm, 166 Tm, 167 Tm, 168 Tm, 170 Tm, 172 Tm, 173 Tm, 230 U, 231 U, 237 U, 240 U, 48 V, 178 W, 181 W, 185 W, 187 W, 188 W, 122 Xe, 125 Xe, 127 Xe, 129 mXe, 131 mXe, 133 Xe, 133 m Xe, 135 Xe, 85 mY, 86 Y, 87 Y, 87 m Y, 88 Y, 90 Y, 90 mY, 91 Y, 92 Y, 93 Y, 166 Yb, 169 Yb, 175 Yb, 62 Zn, 65 Zn, 69 mZn, 71 mZn, 72 Zn, 86 Zr, 88 Zr, 89 Zr, 95 Zr, and 97 Zr.

14 . A composition of claim 13 , wherein the radionuclide comprises 90 Y, 67 Cu, 213 Bi, 212 Bi, 186 Re, 67 Cu 90 Y, 213 Bi, 177 Lu, 186 Re, or 67 Ga.

15 . A composition of claim 13 , wherein the radionuclide comprises 89 Zr, 225 Ac, or 227 Th.

16 . A composition of claim 12 , wherein the metal comprises a daughter isotope of a radionuclide.

17 . A composition of claim 16 , wherein the daughter isotope of the radionuclide comprises 89 Y, 18 O, 221 Fr, 213 Bi, or 209 Pb.

18 . A kit comprising a composition of claim 1 and a metal.

19 . A kit of claim 18 , wherein the metal is a radionuclide.

20 . A kit of claim 19 , wherein the radionuclide comprises 225 Ac, 226 Ac, 228 Ac, 105 Ag, 106 mAg, 110 mAg, 111 Ag, 112 Ag, 113 Ag, 239 Am, 240 Am, 242 Am, 244 Am, 37 Ar, 71 As, 72 As, 73 As, 74 As, 76 As, 77 As, 209 At, 210 At, 191 Au, 192 Au, 193 Au, 194 Au, 195 Au, 196 Au, 196 m 2 Au, 198 Au, 198 mAu, 199 Au, 200 mAu, 128 Ba, 131 Ba, 133 mBa, 135 mBa, 140 Ba, 7 Be, 203 Bi, 204 Bi, 205 Bi, 206 Bi, 210 Bi, 212 Bi, 243 Bk, 244 Bk, 245 Bk, 246 Bk, 248 mBk, 250 Bk, 76 Br, 77 Br, 80 mBr, 82 Br, 11 C, 14 C, 45 Ca, 47 Ca, 107 Cd, 115 Cd, 115 mCd, 117 mCd, 132 Ce, 133 mCe, 134 Ce, 135 Ce, 137 Ce, 137 mCe, 139 Ce, 141 Ce, 143 Ce, 144 Ce, 246 Cf, 247 Cf, 253 Cf, 254 Cf, 240 Cm, 241 Cm, 242 Cm, 252 Cm, 55 Co, 56 Co, 57 Co, 58 Co, 58 mCo, 6 Co, 48 Cr, 51 Cr, 127 Cs, 129 Cs, 131 Cs, 132 Cs, 136 Cs, 137 Cs, 61 Cu, 62 Cu, 64 Cu, 67 Cu, 153 Dy, 155 Dy, 157 Dy, 159 Dy, 165 Dy, 166 Dy, 160 Er, 161 Er, 165 Er, 169 Er, 171 Er, 172 Er, 250 Es, 251 Es, 253 Es, 254 Es, 254 mEs, 255 Es, 256 mEs, 145 Eu, 146 Eu, 147 Eu, 148 Eu, 149 Eu, 150 mEu, 152 mEu, 156 Eu, 157 Eu, 52 Fe, 59 Fe, 251 Fm, 252 Fm, 253 Fm, 254 Fm, 255 Fm, 257 Fm, 66 Ga, 67 Ga, 68 Ga, 72 Ga, 73 Ga, 146 Gd, 147 Gd, 149 Gd, 151 Gd, 153 Gd, 159 Gd, 68 Ge, 69 Ge, 71 Ge, 77 Ge, 170 Hf, 171 Hf, 173 Hf, 175 Hf, 179 m 2 Hf, 180 mHf, 181 Hf, 184 Hf, 192 Hg, 193 Hg, 193 mHg, 195 Hg, 195 mHg, 197 Hg, 197 mHg, 203 Hg, 160 mHo, 166 Ho, 167 Ho, 123 I, 124 I, 126 I, 130 I, 132 I, 133 I, 135 I, 109 In, 110 In, 111 In, 114 mIn, 115 mIn, 184 Ir, 185 Ir, 186 Ir, 187 Ir, 188 Ir, 189 Ir, 190 Ir, 190 m 2 Ir, 192 Ir, 193 mIr, 194 Ir, 194 m 2 Ir, 195 mIr, 42 K, 43 K, 76 Kr, 79 Kr, 81 mKr, 85 mKr, 132 La, 133 La, 135 La, 140 La, 141 La, 262 Lr, 169 Lu, 170 Lu, 171 Lu, 172 Lu, 174 mLu, 176 mLu, 177 Lu, 177 mLu, 179 Lu, 257 Md, 258 Md, 260 Md, 28 Mg, 52 Mn, 90 Mo, 93 mMo, 99 Mo, 13 N, 24 Na, 90 Nb, 91 mNb, 92 mNb, 95 Nb, 95 mNb, 9 % Nb, 138 Nd, 139 mNd, 140 Nd, 147 Nd, 56 Ni, 57 Ni, 66 Ni, 234 Np, 236 mNp, 238 Np, 239 Np, 15 O, 182 Os, 183 Os, 183 mOs, 185 Os, 189 mOs, 191 Os, 191 mOs, 193 Os, 32 P, 33 P, 228 Pa, 229 Pa, 230 Pa, 232 Pa, 233 Pa, 234 Pa, 200 Pb, 201 Pb, 202 mPb, 203 Pb, 209 Pb, 212 Pb, 100 Pd, 101 Pd, 103 Pd, 109 Pd, 111 mPd, 112 Pd, 143 Pm, 148 Pm, 148 mPm, 149 Pm, 151 Pm, 204 Po, 206 Po, 207 Po, 210 Po, 139 Pr, 142 Pr, 143 Pr, 145 Pr, 188 Pt, 189 Pt, 191 Pt, 193 mPt, 195 mPt, 197 Pt, 200 Pt, 202 Pt, 234 Pu, 237 Pu, 243 Pu, 245 Pu, 246 Pu, 247 Pu, 223 Ra, 224 Ra, 225 Ra, 81 Rb, 82 Rb, 82 mRb, 83 Rb, 84 Rb, 86 Rb, 181 Re, 182 Re, 182 mRe, 183 Re, 184 Re, 184 mRe, 186 Re, 188 Re, 189 Re, 190 mRe, 99 Rh, 99 mRh, 100 Rh, 101 mRh, 102 Rh, 103 mRh, 105 Rh, 211 Rn, 222 Rn, 97 Ru, 103 Ru, 105 Ru, 35 S, 118 mSb, 119 Sb, 120 Sb, 120 mSb, 122 Sb, 124 Sb, 126 Sb, 127 Sb, 128 Sb, 129 Sb, 43 Sc, 44 Sc, 44 mSc, 46 Sc, 47 Sc, 48 Sc, 72 Se, 73 Se, 75 Se, 153 Sm, 156 Sm, 110 Sn, 113 Sn, 117 mSn, 119 mSn, 121 Sn, 123 Sn, 125 Sn, 82 Sr, 83 Sr, 85 Sr, 89 Sr, 91 Sr, 173 Ta, 175 Ta, 176 Ta, 177 Ta, 180 Ta, 182 Ta, 183 Ta, 184 Ta, 149 Tb, 150 Tb, 151 Tb, 152 Tb, 153 Tb, 154 Tb, 154 mTb, 154 m 2 Tb, 155 Tb, 156 Tb, 156 mTb, 156 m 2 Tb, 160 Tb, 161 Tb, 94 Tc, 95 Tc, 95 mTc, 96 Tc, 97 mTc, 99 mTc, 118 Te, 119 Te, 119 mTe, 121 Te, 121 mTe, 123 m Te, 125 mTe, 127 Te, 127 mTe, 129 mTe, 131 mTe, 132 Te, 227 Th, 231 Th, 234 Th, 45 Ti, 198 Tl, 199 Tl, 200 Tl, 201 Tl, 202 Tl, 204 Tl, 165 Tm, 166 Tm, 167 Tm, 168 Tm, 170 Tm, 172 Tm, 173 Tm, 230 U, 231 U, 237 U, 240 U, 48 V, 178 W, 181 W, 185 W, 187 W, 188 W, 122 Xe, 125 Xe, 127 Xe, 129 mXe, 131 mXe, 133 Xe, 133 m Xe, 135 Xe, 85 mY, 36 Y, 87 Y, 87 m Y, 88 Y, 90 Y, 90 m Y, 91 Y, 92 Y, 93 Y, 166 Yb, 169 Yb, 175 Yb, 62 Zn, 65 Zn, 69 mZn, 71 mZn, 72 Zn, 86 Zr, 88 Zr, 89 Zr, 95 Zr, and 97 Zr.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2022
From: FRED HUTCHINSON CANCER CENTER
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 061724/0791 →
MERGER AND CHANGE OF NAME Recorded Oct 27, 2022
From: FRED HUTCHINSON CANCER RESEARCH CENTER; SEATTLE CANCER CARE ALLIANCE
To: FRED HUTCHINSON CANCER CENTER
Reel/Frame 061792/0210 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2021
From: STRONG, ROLAND K.
To: FRED HUTCHINSON CANCER RESEARCH CENTER
Reel/Frame 055782/0787 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2019
From: ABERGEL, REBECCA J.; CAPTAIN, ILYA; REES, JULIAN
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 049458/0026 →
CONFIRMATORY LICENSE Recorded Jun 13, 2019
From: UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB
To: UNITED STATES DEPARTMENT OF ENERGY
Reel/Frame 049460/0336 →
Continuity (2)
Provisional Application 62401687 · Sep 29, 2016
Related Publication 20210009510A1 · Jan 14, 2021
References Cited (354)
US 3323857A · Bauer · 1967 [cited by applicant]
US 3634113A · Fhrenbacher · 1972 [cited by applicant]
US 4025602A · Campbell · 1977 [cited by applicant]
US 4278559A · Levenson et al. · 1981 [cited by applicant]
US 4698431A · Raymond et al. · 1987 [cited by applicant]
US 4891075A · Dakubu · 1990 [cited by applicant]
US 5442116A · Welch et al. · 1995 [cited by applicant]
US 5482570A · Saurer et al. · 1996 [cited by applicant]
US 5510091A · Rais · 1996 [cited by applicant]
US 5571894A · Wels et al. · 1996 [cited by applicant]
US 5587458A · King et al. · 1996 [cited by applicant]
US 5591828A · Bosslet et al. · 1997 [cited by applicant]
US 5624901A · Raymond · 1997 [cited by examiner]
US 5634901A · Alba et al. · 1997 [cited by applicant]
US 5753204A · Huston et al. · 1998 [cited by applicant]
US 5826161A · Madic et al. · 1998 [cited by applicant]
US 5869046A · Presta et al. · 1999 [cited by applicant]
US 5892029A · Raymond et al. · 1999 [cited by applicant]
US 6221476B1 · Bruening et al. · 2001 [cited by applicant]
US 6843917B1 · Guy et al. · 2005 [cited by applicant]
US 6846915B2 · Raymond et al. · 2005 [cited by applicant]
US 8361794B2 · Jakobsen et al. · 2013 [cited by applicant]
US 8475747B1 · Johnson et al. · 2013 [cited by applicant]
US 8557601B2 · Raymond et al. · 2013 [cited by applicant]
US 8933526B2 · Tsakalakos et al. · 2015 [cited by applicant]
US 9123846B2 · Le Perchec et al. · 2015 [cited by applicant]
US 9472694B2 · Dionne et al. · 2016 [cited by applicant]
US 9556122B2 · Raymond et al. · 2017 [cited by applicant]
US 10982136B2 · Agbo et al. · 2021 [cited by applicant]
US 11684614B2 · Abergel et al. · 2023 [cited by applicant]
US 12002595B2 · Abergel et al. · 2024 [cited by applicant]
US 20020122752A1 · Fukasawa et al. · 2002 [cited by applicant]
US 20050008570A1 · Raymond et al. · 2005 [cited by applicant]
US 20090184051A1 · Heres et al. · 2009 [cited by applicant]
US 20090320646A1 · Yaita et al. · 2009 [cited by applicant]
US 20100015725A1 · Raymond et al. · 2010 [cited by applicant]
US 20100261902A1 · Xu · 2010 [cited by applicant]
US 20100317117A1 · Peterson · 2010 [cited by applicant]
US 20110250138A1 · Fan et al. · 2011 [cited by applicant]
US 20120132277A1 · Sulima et al. · 2012 [cited by applicant]
US 20120214843A1 · Durbin-Harvey et al. · 2012 [cited by applicant]
US 20140039169A1 · Raymond et al. · 2014 [cited by applicant]
US 20140235680A1 · Bergeron et al. · 2014 [cited by applicant]
US 20160289223A1 · Bergeron · 2016 [cited by applicant]
US 20160362491A1 · Mudde et al. · 2016 [cited by applicant]
US 20170298272A1 · Agbo et al. · 2017 [cited by applicant]
US 20170360956A1 · Butlin et al. · 2017 [cited by applicant]
US 20190183868A1 · Abergel et al. · 2019 [cited by applicant]
US 20190287691A1 · Abergel et al. · 2019 [cited by applicant]
US 20190382470A1 · Himmler et al. · 2019 [cited by applicant]
US 20210283115A1 · Abergel et al. · 2021 [cited by applicant]
US 20220152003A1 · Abergel et al. · 2022 [cited by applicant]
CA 3022852A1 · 2017 [cited by applicant]
CA 3035966A1 · 2018 [cited by applicant]
CA 3038670A1 · 2018 [cited by applicant]
CA 3038723A1 · 2018 [cited by applicant]
CN 104825389 · 2015 [cited by applicant]
CN 104998251 · 2015 [cited by applicant]
EP 0404097B1 · 1990 [cited by applicant]
EP 1755586A2 · 2007 [cited by applicant]
EP 3452040A1 · 2019 [cited by applicant]
EP 3509595A1 · 2019 [cited by applicant]
EP 3519034A1 · 2019 [cited by applicant]
EP 3520117A2 · 2019 [cited by applicant]
EP 3520117B1 · 2023 [cited by applicant]
JP 2008525812 · 2008 [cited by applicant]
JP 2019514944A · 2019 [cited by applicant]
JP 2019532040A · 2019 [cited by applicant]
JP 2019532182A · 2019 [cited by applicant]
JP 7018210B2 · 2022 [cited by applicant]
WO WO199301161A1 · 1993 [cited by applicant]
WO WO199316185A2 · 1993 [cited by applicant]
WO WO2006028523 · 2006 [cited by applicant]
WO WO2006072620A1 · 2006 [cited by applicant]
WO WO2007098934A1 · 2007 [cited by applicant]
WO WO2007118904 · 2007 [cited by applicant]
WO WO2010129962 · 2010 [cited by applicant]
WO WO2015077655A1 · 2015 [cited by applicant]
WO WO2017105565 · 2017 [cited by applicant]
WO WO2017192581A1 · 2017 [cited by applicant]
WO WO2018048812A1 · 2018 [cited by applicant]
WO WO2018063638A1 · 2018 [cited by applicant]
WO WO2018097871A2 · 2018 [cited by applicant]
Sturzbecher-Hoehne et al, Dalton Trans., vol. 40, pp. 8340-8346 (Year: 2011). [cited by examiner]
Moore et al, Inorg. Chem., vol. 49, No. 21, pp. 9928-9939 (Year: 2010). [cited by examiner]
Chatterjee et al (American Association of Pharmaceutical Scientists, Chapter 24, Excipients and Active Pharmaceutical Ingredients, pp. 347-361). (Year: 2014). [cited by examiner]
Uhlir et al , J. Med. Chem., vol. 36, pp. 504-509 (Year: 1993). [cited by examiner]
PubChem CID 31374—N,N-dimethyleacetamide (date unknown), 3 pages. [cited by examiner]
Werner, 1,2-Hydroxypyridonate/Terephthalamide Complexes of Gadolinium(III): Synthesis, Stability, Relaxivity, and Water Exchange Properties, Inorganic Chemistry (2009), 48(1), 277-286) (Year: 2009). [cited by examiner]
Office Action dated Jun. 10, 2021 in U.S. Appl. No. 16/365,132, dated Mar. 26, 2019. [cited by applicant]
Japanese Office Action dated Oct. 26, 2021 in JP 2019-516989. [cited by applicant]
Corrected Notice of Allowability dated Nov. 10, 2021 in U.S. Appl. No. 16/330,601. [cited by applicant]
Office Action dated May 14, 2021 in European Patent Application No. 17793154.0. [cited by applicant]
Extended European Search Report dated Jan. 19, 2021 in Application No. 17857076.8. [cited by applicant]
Office Action dated Oct. 26, 2021 in Japanese Application No. 2019-516989. [cited by applicant]
Durbin, P. et al., “Octadentate catecholamide ligands for Pu (IV) based on linear or preorganized molecular backbones”, Human Toxicology, Macmillan Publishers, Basingstoke GB, vol. 15, No. 4, pp. 352-360, 1996. [cited by applicant]
Gans, et al., Glee, a new computer program for glass electrode calibration, Talanta, vol. 51, No. 1, pp. 33-37, 2000. [cited by applicant]
Sam II, AD et al. Safety of gadolinium contrast angiography in patients with chronic renal Insufficiency Journal of Vascular Surgery, vol. 38, pp. 313-318, (2003). [cited by applicant]
Uhlir, Linda et al., “Specific sequestering agents for the actinides. 21. Synthesis and initial biological testing of octadentate mixed catecholate-hydroxypyridinonate ligands”, Journal of Medicinal Chemistry, vol. 36, … [cited by applicant]
Office Action Dated Jan. 2, 2020 in U.S. Appl. No. 15/442,441. [cited by applicant]
Office Action Dated Apr. 9, 2020 in U.S. Appl. No. 15/442,441. [cited by applicant]
Office Action Dated Mar. 10, 2020 in U.S. Appl. No. 16/097,782. [cited by applicant]
Office Action Dated Oct. 15, 2019 in U.S. Appl. No. 16/097,782. [cited by applicant]
Office Action Dated Jun. 25, 2019 in U.S. Appl. No. 16/097,782. [cited by applicant]
Supplementary Partial European Search Report, re Application No. 17873523.9, dated May 27, 2020. [cited by applicant]
Office Action Dated Jul. 22, 2020 in U.S. Appl. No. 16/097,782. [cited by applicant]
European Search Report, re Application No. 17873523.9, dated Aug. 27, 2020. [cited by applicant]
Supplementary Partial European Search Report, re Application No. 17857076.8, dated Oct. 7, 2020. [cited by applicant]
Naasani, Imad et al., Improving the Oral Bioavailability of Sulpiride by Sodium Oleate in Rabbits, J. Pharm., vol. 47, pp. 469-473, 1995. [cited by applicant]
Office Action Dated Jul. 13, 2021 in U.S. Appl. No. 16/330,601. [cited by applicant]
Office Action dated Jul. 28, 2021 in JP 2019-512761. [cited by applicant]
Notice of Reasons for Rejection dated Apr. 26, 2021 in Japanese Patent Application No. JP 2018-557384. [cited by applicant]
Abergel, et al. Biomimetic Actinide Chelators: An Update on the Preclinical Development of the Orally Active Hydroxypyridonate Decorporation Agents 3,4,3-L/(1,2-HOPO) and 5-LIO(Me-3,2-HOPO). Health Physics, vol. 99, No.… [cited by applicant]
Abergel, et al. Using the Antenna Effect as a Spectroscopic Tool; Photophysics and Solution Thermodynamics of the Model Luminescent Hydroxypyridonate Complex [EuIII(3,4,3-LI(1,2-HOPO))], Inorganic Chemistry, vol. 48, No… [cited by applicant]
Abergei, et al., Multidentate Terephthalamidate and Hydroxypyridonate Ligands: Towards New Orally Active Chelators, Hemoglobin, vol. 35, No. 3, pp. 276-290, 2011. [cited by applicant]
Agbo et al., Enhanced ultraviolet photon capture in ligand-sensitized nanocrystals, ACS Photonics, vol. 3, pp. 547-552, 2016. [cited by applicant]
Agbo et al., Ligand-Sensitized Lanthanide Nanocrystals: Merging Solid-State Photophysics and Molecular Solution Chemistry, Inorganic Chemistry, vol. 55, No. 20, pp. 9973-9980, 2016. [cited by applicant]
Agency for Toxic Substances and Disease Registry (ATSDR), Toxicological profile for Plutonium. 2010, U.S. Department of Health and Human Services, Public Health Service: Atlanta, GA. [cited by applicant]
Alderighi, et al., Hyperquad Simulation and Speciation (HySS): A Utility Program for the Investigation of Equilibria Involving Soluble and Partially Soluble Species, Coordination Chemistry Reviews, vol. 184, pp. 311-318… [cited by applicant]
Allred, B. et al. Siderocalin-mediated recognition, sensitization, and cellular uptake of actinides. Proceedings of the National Academy of Sciences of the United States of America, vol. 112, pp. 10342, 2015. [cited by applicant]
An, et al., Elimination Profiles After Delayed Treatment With 3,4,3L/(1,2HOPO) in Female and Male Swiss-Webster Mice. International Journal of Radiation Biology, vol. 90, No. 11, pp. 1055-1061, 2014. [cited by applicant]
An, et al., From Early Prophylaxis to Delayed Treatment: Establishing the Plutonium Decorporation Activity Window of Hydroxypyridinonate Chelating Agents, Chemico-Biological Interactions, Elsevier Science Ireland, IR, v… [cited by applicant]
Ansari, et al., Extraction of actinides using N, N,N , N-Tetraoctyl Diglycolamide (TODGA): A Thermodynamic Study Radiochimica. Acta Journal, vol. 94, pp. 307-312, 2006. [cited by applicant]
Ansari, et al., N,N,N′,N′-Tetraoctyl Diglycolamide (Todga): A Promising Extractant for Actinide-Partitioning from High-Level Waste (HLW), Solvent Extraction and Ion Exchange, pp. 463-479, 2006. [cited by applicant]
Antonio, M. et al., Berkelium redox speciation, Radiochim. Acta, vol. 90, pp. 851-856, (2006). [cited by applicant]
Argonne National Laboratory Division of Biological and Medical Research, Annual Report, Argonne National Laboratory. Division of Biological and Medical Research: Argonne, Illinois. 1979. [cited by applicant]
Baco, et al., Diphenyl-Benzo[1,3]dioxole-4-Carboxylic Acid Pentafluorophenyl Ester: A Convenient Catechol Precursor in the Synthesis of Siderophore Vectors Suitable for Antibiotic Trojan Horse Strategies, Organic and Bi… [cited by applicant]
Banker, et al., Pharmaceutics and Pharmacy Practice, pp. 238-250, 1982. [cited by applicant]
Banski, M. et al., NaYF4 nanocrystals with TOPO ligands: synthesis-dependent structural and luminescent properties, Physical Chemistry Chemical Physics, vol. 15, No. 47, pp. 19232-19241, 2013. [cited by applicant]
Baral, T. et al., Experimental Therapy of African Trypanosomiasis With a Nanobody-Conjugated Human Trypanolytic Factor, Nature Medicine, vol. 12, pp. 580-584, 2006. [cited by applicant]
Barthelemy, et al., Journal of Biological Chemistry, pp. 3283-3639, 2008. [cited by applicant]
Baybarz, et al. Absorption Spectra of Bk(III) and Bk(IV) in Several Media, Journal of Inorganic and Nuclear Chemistry, Vo. 34, pp. 739-746, 1972. [cited by applicant]
Bhattacharyya, M. et al., Action of DTPA on Hepatic Plutonium: III. Evidence for a Direct Chelation Mechanism for DTPA-Induced Excretion of Monomeric Plutonium into Rat Bile, Radiation Research, vol. 80, pp. 108-115, 19… [cited by applicant]
Binz, et al., Engineering Novel Binding Proteins From Nonimmunoglobulin Domains, Nature Biotechnology, vol. 23, pp. 1257-1268, 2005. [cited by applicant]
Bird, et al., Single-chain antigen-binding proteins, Science, vol. 242, No. 4877, pp. 423-426, 1988. [cited by applicant]
Boersma, et al., DARPins and Other Repeat Protein Scaffolds: Advances in Engineering and Applications, Current Opinion in Biotechnology, vol. 22, No. 4, pp. 849-857, 2011. [cited by applicant]
Bunin, et al., Dose-Dependent Efficacy and Safety Toxicology of Hydroxypyridinonate Actinide Decorporation Agents in Rodents: Towards a Safe and Effective Human Dosing Regimenm Radiation Research, vol. 179, No. 2, pp. 1… [cited by applicant]
Bünzlil, et al., Lanthanide Luminescence for Biomedical Analyses and Imaging, Chemical Reviews, vol. 110, No. 5, pp. 2729-2755, 2010. [cited by applicant]
Bünzlil, et al. Taking Advantage of Luminescent Lanthanide Ions, Chemical Society Reviews, vol. 34, No. 12, pp. 1048-1077, 2005. [cited by applicant]
Carnall, et al., A Systematic Analysis of the Spectra the Trivalent Actinide Chlorides in D3h Site Symetry, Argonne National Laboratory, Argonne , Illinois, USA, 1989. [cited by applicant]
Carott, et al., Distribution of plutonium, americium and interfering fission products between nitric acid and a mixed organic phase of TODGA and DMDOHEMA in kerosene, and implications for the design of the “Euro-Ganex” … [cited by applicant]
Carrot, et al. Neptunium Extraction and Stability in the Ganex Solvent: 0.2 M Todga/0.5 M Dmdohema/ Kerosene, Solvent Extraction and Ion Exchange, 2012. [cited by applicant]
Captain, et al., Engineered Recognition of Tetravalent Zirconium and Thorium by Chelator—Protein Systems: Toward Flexible Radiotherapy and Imaging Platforms, Inorganic Chemistry, vol. 55, pp. 11930-11936, 2016. [cited by applicant]
Cassatt, et al., Medical Countermeasures Against Nuclear Threats: Radionuclide Decorporation Agents., Radiation Research, vol. 170, No. 4, pp. 540-548, 2008. [cited by applicant]
Chang, et al., Analytical Methods for the Bioavailability Evaluation of Hydroxypyridinonate Actinide Decorporation Agents in Pre-Clinical Pharmacokinetic Studies, Journal Chromatography Separation Technique Journal, 201… [cited by applicant]
Chen, et al. Core/Shell NaGdF4:Nd3+/NaGdF4 Nanocrystals with Efficient Near-Infrared to Near-Infrared Downconversion Photoluminescence for Bioimaging Applications, ACS Nano, vol. 6, No. 4, pp. 2969-2977, 2012. [cited by applicant]
Choi, et al., Biodistribution of the Multidentate Hydroxypyridinonate Ligand [(14) CJ-3,4,3-L/(1,2-HOPO), a Potent Actinide Decorporation Agent, Drug Development Research, vol. 76, No. 3, pp. 107-122, 2015. [cited by applicant]
Choi, et al., In vitro metabolism and stability of the actinide chelating agent 3,4,3-Lf {1,2-I-/OPO). Journal of pharmaceutical sciences, vol. 104, No. 5, pp. 1832-1838, 2015. [cited by applicant]
Choi, et al., Understanding the Health Impacts and Risks of Exposure to Radiation, in Reflections on the Fukushima Daiichi Nuclear Accident, Chemical Sciences Division, Lawrence Berkeley National Laboratory, pp. 259-281… [cited by applicant]
Chudinov, et al., The separation of berkelium (III) from cerium (III), Journal of Radioanalytical and Nuclear Chemistry, vol. 10, pp. 41-46, 1972. [cited by applicant]
Cortez-Retamozo, V. et al., Efficient Cancer Therapy with a Nanobody-Based Conjugate, Cancer Research, vol. 64, pp. 2853-2857, 2004. [cited by applicant]
Cotton, et al., Wiley, 2006. http://www.wiley.com/WileyCDA/WileyTitle/productCd-0470010053.html. [cited by applicant]
Daumann, et al. New Insights into Structure and Luminescence of Eu(III) and Sm(III) Complexes of the 3,4,3-Li(1,2-HOPO) Ligand, Journal of the American Chemical Society, vol. 137, pp. 2816-2819, 2015. [cited by applicant]
Deblonde, et al., A New Strategy for the Purification of Heavy Actinides and Medical Radioisotopes, Advanced Techniques in Actinide Spectroscopy, 2018. [cited by applicant]
Deblonde, et al., Chelation and stabilization of berkelium in oxidation state +IV, Nature Chemistry, vol. 9, pp. 843-849, 2017. [cited by applicant]
Deblonde, et al., Complexation, Characterization and Separation of the Lanthanides and Actinides: Shedding Light to Subtle Differences within the f-element Series, Actinides and Rare Earths Focus Topic, 2018. [cited by applicant]
Deblonde, et al., Solution Thermodynamic Stability of Complexes Formed with the Octadentate Hydroxypyridinonate Ligand 3,4,3-LI(1,2-HOPO): A Critical Feature for Efficient Chelation of Lanthanide(IV) and Actinide(IV) Io… [cited by applicant]
Deblonde, et al., 1387—Hydropyridinonate ligands: From iron(III) to berkelium(IV) chemistry, Abstract. [cited by applicant]
Deblonde, et al., Inducing Selectivity and Chirality in Group IV Metal Coordination With High-Denticity Hydroxypyridinonest, Dalton Transactions, No. 23, 2019. [cited by applicant]
Deblonde, et al., Solution Thermodynamics and Kinetics of Metal Complexation with a Hydroxypyridinone Chelator Designed for Thorium-227 Targeted Alpha Therapy, Inorganic Chemistry, vol. 57, pp. 14337-14346, 2018. [cited by applicant]
Deblonde, et al., Solution thermodynamics of hydropyridinonate 4f and 5f complexes, 28th Rare Earth Research Conference, 2017. [cited by applicant]
Deblonde, et al., Toxic heavy metal—Pb, Cd, Sn—complexation by the octadentate hydroxypyridinonate ligand archetype 3,4,3-LI(1,2-HOPO)†, New Journal of Chemistry, vol. 42, pp. 7649-7658, 2018. [cited by applicant]
Deblonde, et al., Ultra-selective Ligand-driven Separation of Strategic Actinides, Nature Communications, 2019. [cited by applicant]
Deblonde, et al., Inorganic chemistry, vol. 52, No. 15, pp. 8805-8811,2013. [cited by applicant]
Delmau, et al., Extraction of Trivalent Actinides and Lanthanides from Californium Campaign Rework Solution Using Todga-based Solvent Extraction System, Oak Ridge National Laboratory, 2017. [cited by applicant]
Deri, et al., Alternative Chelator for 89Zr Radiopharmaceuticals: Radiolabeling and Evaluation of 3,4,3-(LI-1,2-HOPO), Journal of Medicinal Chemistry, vol. 57, No. 11, pp. 4849-4860, 2014. [cited by applicant]
Deri, et al., Bioconjugate Chemistry, vol. 26, No. 12, pp. 2579-2591, 2015. [cited by applicant]
Deri, et al., A Superior Bifunctional Chelator for 89Zr ImmunoPET, Bioconjugate Chemistry, vol. 26, No. 12, pp. 2579-2591, 2015. [cited by applicant]
Designing a Process for Selecting a Site for a Deep-Mined, Geologic Repository for High Level Radioactive Waste and Spent Nuclear Fuel, United States Nuclear Waste Technical Review Board, pp. 1-228, 2015. [cited by applicant]
Durbin, et al. Actinides in Animals and Man, in the Chemistry of the Actinide and Transactinide Elements, L.R. Morss, N.M. Edelstein, and J. Fuger, Editors, pp. 3339-3340, 2006. [cited by applicant]
Durbin, et al., Gross Composition and Plasma and Extracellular Water Volumes of Tissues of a Reference Mouse, Health Physics, vol. 63, No. 4, pp. 427-442, 1992. [cited by applicant]
Durbin, et al., Lecture: The Quest for Therapeutic Actinide Chelators, Health Physics, vol. 95, No. 5, pp. 465-492, 2008. [cited by applicant]
Dutta, et al., Studies on separation of 90Y and 90Sr separation from hydrochloric acid solutions using Todga as the extractant by SLM method, Procedia Chemistry, vol. 7, pp. 191-194, 2012. [cited by applicant]
Fritsch, et al., Simplified Structure of a New Model to Describe Urinary Excretion of Plutonium After Systemic, Liver or Pulmonary Contamination of Rats Associated With Ca-DTPA Treatments, Radiation Research, vol. 171, … [cited by applicant]
Fritsch, et al., Structure of a Single Model to Describe Plutonium and Americium Decorporation by DTPA treatments, Health Physics, vol. 99, No. 4, pp. 553-559, 2010. [cited by applicant]
Gans, et al., Investigation of Equilibria in Solution. Determination of Equilibrium Constants with the Hyperquad Suite of Programs, Talanta, vol. 43, pp. 1739-1753, 1996. [cited by applicant]
Gennaro, et al., Remington: The Science and Practice of Pharmacy, 20th ed, 2003. [cited by applicant]
Goetz, et al., The Neutrophil Lipocalin NGAL Is a Bacteriostatic Agent That Interferes With Siderophore-Mediated Iron Acquisition, Molecular Cell, vol. 10, pp. 1033-1043, 2002. [cited by applicant]
Gorden, et al., Rational Design of Sequestering Agents for Plutonium and Other Actinides, Chemical Reviews, vol. 103, pp. 4207-4282, 2003. [cited by applicant]
Grappin, et al., Treatment of actinide exposures: A review oJCa-DTPA injections inside CEA-COGEMA plants, Radiation Protection Dosimetry, vol. 127, pp. 435-439, 2007. [cited by applicant]
Gregoric, et al., Characterization and Leaching of Neodymium Magnet Waste and Solvent Extraction of the Rare-Earth Elements Using Todga, Journal of Sustain. Metall, vol. 3, pp. 638-645, 2017. [cited by applicant]
Grimes, et al., Trivalent Lanthanide/Actinide Separation Using Aqueous-Modified Talspeak Chemistry, Solvent Extraction and Ion Exchange, vol. 32, No. 4, pp. 378-390, 2014. [cited by applicant]
Gutmacher, et al., The absorption spectra of Bk3+ and Bk4+ in solution, Journal of Inorganic and Nuclear Chemistry, vol. 29, pp. 2341-2345, 1967. [cited by applicant]
Gutmacher, et al., Stability of Tetravalent Berkelium in Acid Solution and the Absorption Spectra of Bk(IV) and Bk(III), Journal of Inorganic and Nuclear Chemistry, pp. 979-994, 1973. [cited by applicant]
Harvey, Production of Actinium-225 via High Energy Proton Induced Spallation of Thorium-232. Final Technical Report DE-SC0003602, NorthStar Medical Radioisotopes, LLC, https://world wide web .osti.gov/scitech/servlets/p… [cited by applicant]
Hobart, et al., The Chemistry of the Actinide and Transactinide Elements—Chapter X—Berkelium, Springer, 2006. [cited by applicant]
Hoet, et al., Generation of High-Affinity Human Antibodies by Combining Donor-Derived and Synthetic Complementarity-Determining-Region Diversity, Nature Biotechnology, vol. 23, pp. 344-348, 2005. [cited by applicant]
Holliger, et al., Diabodies: small bivalent and bispecific antibody fragments, Proceedings of the National Academy of Sciences of the USA, vol. 90, pp. 6444-6448, 1993. [cited by applicant]
Hudson, et al., Engineered antibodies, Nature Medicine, vol. 9, pp. 129-134, 2003. [cited by applicant]
Husain, et al., Extraction chromatography of lanthanides using N,N,N′,N′-tetraoctyl diglycolamide (Todga) as the stationary phase, Desalination, vol. 229, pp. 294-301, 2008. [cited by applicant]
Huston, et al., Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fv Analogue Produced in [cited by applicant]
Iqbal, et al., Synthesis and Am/Eu extraction of novel Todga derivatives, Supramolecualr Chemistry, vol. 22, pp. 827-837, 2010. [cited by applicant]
Jang, et al. Bright dual-mode green emission from selective set of dopant ions in β-Na(Y,Gd)F4:Yb,Er/β-NaGdF4:Ce, Tb core/shell nanocrystals, Optics Express, vol. 20, No. 15, pp. 17107-17118, (2012). [cited by applicant]
Jarvis, et al., Significance of Single Variables in Defining Adequate Animal Models to Assess the Efficacy of New Radionuclide Decorporation Agents: Using the Contamination Dose as an Example. Drug Development Research,… [cited by applicant]
Burgaada, et al., Journal of Labelled Compounds and Radiopharmaceuticals, vol. 44, pp. 13-19, 2001. [cited by applicant]
Jursich, et al., Laser induced fluorescence of 249 Bk 4+ in CeF 4, Inorganica Chim. Acta. vol. 139, pp. 273-274. 1987. [cited by applicant]
Konzen, et al., Development of the Plutonium-DTPA Biokinetic Model. Health Physics, vol. 108, No. 6, pp. 565-573, 2015. [cited by applicant]
Kurkoti, et al., Gadolinium and nephrogenic systemic fibrosis: Association or causation. 1-10 Nephrology, vol. 13, pp. 235-241, 2008. [cited by applicant]
Kullgren, et al., Actinide Chelation: Biodistribution and In Vivo Complex Stability of the Targeted Metal Ions, Toxicology Mechanisms and Methods, vol. 23, No. 1, pp. 18-26, 2013. [cited by applicant]
Lakowicz, et al., Energy Transfer, Principles of Fluorescence Spectroscopy, pp. 367-394, 2006. [cited by applicant]
Lake, et al., Construction and Binding Analysis of Recombinant Single-Chain TCR Derived From Tumor-Infiltrating Lymphocytes and a Cytotoxic T Lymphocyte Clone Directed Against MAGE-1, International Immunology, Vo. 11, p… [cited by applicant]
Lakshminarayana, et al., Cooperative downconversion luminescence in Pr3+/Yb3+:SiO2—Al2O3—BaF2—GdF3 glasses, Journal of Materials Research, vol. 23, Issue 11, pp. 3090-3095, 2008. [cited by applicant]
Li, et al., Engineering Homogeneous Doping in Single Nanoparticle to Enhance Upconversion Efficiency, Nano Lett., vol. 14, No. 6, pp. 3634-3639, 2014. [cited by applicant]
Li, et al., Enhanced NIR downconversion luminescence by precipitating nano Ca5(PO4)3F crystals in Eu2+—Yb3+ co-doped glass, Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, vol. 114, pp. 575-578, 201… [cited by applicant]
Li, et al. Nd3+ Sensitized Up/Down Converting Dual-Mode Nanomaterials for Efficient In-vitro and In-vivo Bioimaging Excited at 800 nm, Scientific Reports, vol. 3, pp. 3536, 2013. [cited by applicant]
Liu, et al. A Stratgey to Achieve Efficent Dual-Mode Luminscence of EU3+ in Lanthanides Doped Multifunctional NAGdF4 Nanocrystals, Adv Matter, vol. 22, pp. 3266-3271, 2010. [cited by applicant]
Liu, et al. Morphology and Phase-Controlled Synthesis of Monodisperse Lanthanide-Doped NaGdF4 Nanocrystals with Multicolor Photo Luminsence, Journal of Materials Chemistry, vol. 19, pp. 489-496, 2009. [cited by applicant]
Liu et al., Procedures for a fast separation of berkelium from complex mixtures of reaction products, J. Radioanal. Nucl. Chem. 76, pp. 119-124, 1983. [cited by applicant]
Lohithakshan, et al., Solvent extraction studies of plutonium(IV) and americium(III) in room temperature ionic liquid (RTIL) by di-2-ethyl hexyl phosphoric acid (HDEHP) as Extractant, Journal of Radioanalytical and Nucl… [cited by applicant]
Loomis, et al., Inorganic Chemistry, vol. 30, No. 5, pp. 906-911, 1991. [cited by applicant]
Lumetta, et al., An Advanced Talspeak Concept Using 2-Ethylhexylphosphonic Acid Mono-2-Ethylhexyl Ester as the Extractant, Solvent Extraction and Ion Exchange, vol. 33, No. 3, pp. 211-223, 2015. [cited by applicant]
Lundberg, et al., Structural Study of the N,N′-Dimethylpropyleneurea Solvated Lanthanoid(III) Ions in Solution and Solid State with an Analysis of the Ionic Radii of Lanthanoid(III) Ions, Inorganic Chemistry, vol. 49, p… [cited by applicant]
Lundberg, et al., The size of actinoid(III) ions—structural analysis vs. common misinterpretations, Coordination Chemistry Reviews, vol. 318, pp. 131-134, 2016. [cited by applicant]
Martell, et al., NIST Standard Reference Database; National Institute of Standards and Technology: Gaithersburg, MD. [cited by applicant]
Maynard, et al., High-Level Bacterial Secretion of Single-Chain Aβ T-Cell Receptors, Journal of Immunological Methods, vol. 306, pp. 51-67, 2005. [cited by applicant]
Mimum, et al., Bimodal imaging using neodymium doped gadolinium fluoride nanocrystals with near-infrared to near-infrared downconversion luminescence and magnetic resonance properties, Journals of Materials Chemistry B,… [cited by applicant]
Milyukova, et al. Extraction of Bk(IV) with POM—Milyukova, 1986.pdf, J. Radioanal. Nucl. Chem. 104 pp. 81-90, (1986). [cited by applicant]
Modolo, et al., Recovery of Actinides and Lanthanides From High-Level Liquid Waste by Extraction Chromatography Using TODGA+TBP Impregnated Resins, Radiochimica Acta, vol. 95, pp. 391-397, 2007. [cited by applicant]
Modolo, et al., Development of a Todga based Process for Partitioning of Actinides from a Purex Raffinate Part I: Batch Extraction Optimization Studies and Stability Tests, Solvent Extraction and Ion Exchange, 2007. [cited by applicant]
Moore, et al. An octadentate luminescent Eu(III) 1,2-HOPO chelate with potent aqueous stability, Inorganic Chemistry, vol. 46, No. 14, pp. 5468-5470, 2007. [cited by applicant]
Moore, et al., Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma, Blood, Vo. 117, pp. 4542-4551, 2011. [cited by applicant]
Moore, et al. Liquid-liquid Extraction Method for the Separation of Cerium (IV) From Berkelium (IV) and Other Elements, Analytical Chemistry, vol. 41, pp. 1658-1661, 1969. [cited by applicant]
Moore, et al., New Method for Rapid Separation of Berkelium (IV) From Cerium (IV) by Anion Exchange, Analytical Chemistry, vol. 39, pp. 1874-1876, 1967. [cited by applicant]
Moos, et al., Radiation Drugs—A Hot Topic. Drug Development Research, vol. 73, No. 5, pp. 229-231, 2012. [cited by applicant]
Morita, et al. Development of Todga Extraction Process for High-Level Liquid Waste—Preliminary Evaluation of Actinide Separation by Calculation, 2000. [cited by applicant]
Morris, et al., Voltammetric Investigation of the Berkelium(IV/III) Couple in Concentrated Aqueous Carbonate Solutions, Radiochimica Acta, pp. 125-134, 1990. [cited by applicant]
Morss et al., The Chemistry of the Actinide and Transactinide Elements, 4th ed, Springer,(2010). [cited by applicant]
Nash, et al., The Chemistry of Talspeak: A Review of the Science, Solvent Extraction. Ion Exchange Journal, vol. 33, No. 1, pp. 1-55, 2015. [cited by applicant]
NCRP, Management of Persons Contaminated with Radionuclides: Handbook, in NCRP Publication. 2008: Bethesda. [cited by applicant]
Nord, et al., A combinatorial library of an α-helical bacterial receptor domain, Protein Engineering, Design and Selection, vol. 8, No. 6, pp. 601, 1995. [cited by applicant]
Nord, et al., Binding proteins selected from combinatorial libraries of an α-helical bacterial receptor domain, Nature Biotechnology, vol. 15, pp. 772-777, 1997. [cited by applicant]
Nord, et al., Recombinant human factor VIll-specific affinity ligands selected from phage-displayed combinatorial libraries of protein A, European Journal of Biochemistry, vol. 268, pp. 4269-4277, 2001. [cited by applicant]
Nugent, et al., Electron-transfer and fd Absorption Bands of Some Lanthanide and Actinide Complexes and the Standard (II-III) Oxidation Potential for Each Member of the Lanthanide and Actinide Series, The Journal of Phy… [cited by applicant]
Nugent, et al., Intramolecular Energy Transfer and Sensitized Luminescence in Actinide (III). Beta.-Diketone Chelates, The Journal of Physical Chemistry A, vol. 73, pp. 1540-1549, 1969. [cited by applicant]
Ostapenko, et al., Extraction Chromatographic Behavior of Actinium and REE on DGA, Ln and TRU Resins in Nitric Acid Solutions, Journal of Radioanalytical and Nuclear Chemistry, vol. 306, pp. 707-711, 2015. [cited by applicant]
Oxford Dictionary of Biochemistry and Molecular Biology Ed. Anthony Smith, Oxford University Press, Oxford, 2004. [cited by applicant]
Parker, S et al., The McGraw-Hill Dictionary of chemical Terms, 1985. [cited by applicant]
Payne, et al. Possible Stabilization of the Tetravalent Oxidation State of Berkelium and Californium in Acetonitrile With Triphenylarsine Oxide, Inorganica Chimica Acta, vol. 139 , pp. 111-112, 1987. [cited by applicant]
Peppard, et al. Isolation of Berkelium by Solvent Extraction of the Tetravalent Species, Journal of Inorganic and Nuclear Chemistry, vol. 4, pp. 344-348, 1957. [cited by applicant]
Pham, et al., A Macrocyclic Chelator with Unprecedented Th4+ Affinity, Journal of the American Chemical Society, vol. 136, No. 25, pp. 9106-9115, 2014. [cited by applicant]
Plueckthon the Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore, 269-315, 1994. [cited by applicant]
Pokhrel, et al. Stokes emission inGdF3:Nd3+ nanoparticles for bioimaging probe, Nanoscale, vol. 6, No. 3, pp. 1667-1674, 2014. [cited by applicant]
Pourmand, et al., Distribution coefficients of 60 elements on Todga resin: Application to Ca, Lu, Hf, U and Th isotope geochemistry, Talanta, vol. 81, pp. 741-753, 2010. [cited by applicant]
Radchenko et al., Application of Ion Exchange and Extraction Chromatography to the Separation of Actinium From Proton-Irradiated Thorium Metal for Analytical Purposes, Journal of Chromatography, pp. 55-63, 2015. [cited by applicant]
Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990. [cited by applicant]
Ricano, et al. Combinatorial Design of Multimeric Chelating Peptoids for Selective Metal Coordination, Chemical Science, 2019. [cited by applicant]
Shannon, et al., Revised Effective Ionic Radii and Systematic Studies of Interatomic Distances in Halides and Chalcogenides, Acta Crystallographica A32, pp. 751-757, 1976. [cited by applicant]
Shockley, et al. Detailed Balance Limit of Efficiency of p—n Junction Solar Cells, Journal of Applied Physics, vol. 32, No. 3, pp. 510-519, 1961. [cited by applicant]
Smith, et al., NIST Critically selected stability constants of metal complexes database, NIST standard reference database, 2004. [cited by applicant]
Stather, et al., Use of DTPAfor increasing the rate of elimination ofplutonium-238 and americium-241from rodents after their inhalation as the nitrates, Human & Experimental Toxicology, vol. 4, No. 6, pp. 573-582, 1985. [cited by applicant]
Stockley, et al., Absorption Spectra of the Bk(IV)-Bk(III) in several media, Journal of Inorganic and Nuclear Chemistry, vol. 34, pp. 739-746, 1972. [cited by applicant]
Sturzbecher-Hoehne, et al., Highly Luminescent and Stable Hydroxypyridinonate Complexes: A Step Towards New Curium Decontamination Strategies, Chemistry—A European Journal, vol. 20, No. 32, pp. 9962-9968, 2014. [cited by applicant]
Sturzbecher-Hoehne, et al., Hydroxypyridinonate Complex Stability of Group (IV) Metals and Tetravalent f-Block Elements: The Key to the Next Generation of Chelating Agents for Radiopharmaceuticals, Inorganic chemistry, … [cited by applicant]
Sturzbecher-Hoehne, et al. 3,4,3-LI(1,2-HOPO): In vitroformation of highly stable lanthanide complexes translates into efficacious in vivo europium decorporation, Dalton Trans., vol. 40, No. 33, pp. 8340-8346, 2011. [cited by applicant]
Sturzbecher-Hoehne, et al Intramolecular Sensitization of Americium Luminescence in Solution: Shining Light on Short-Lived Forbidden 5f Transitions, Dalton Transactions, vol. 45, pp. 9912-9919, 2016. [cited by applicant]
Sturzbecher-Hoehne, et al., Solution Thermodynamic Evaluation of Hydroxypyridinonate Chelators 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO) for UO2(VI) and Th(IV) Decorporation, Radiochimica Acta, vol. 101, No. 6, pp. 359-… [cited by applicant]
Suzuki, et al., Extraction and separation of Am(III) and Sr(II) by N,N,N ,N-tetraoctyl-3-oxapentanediamide (Todga), Radiochimica Acta vol. 92, pp. 463-466, 2004. [cited by applicant]
Tachimori, et al. Modification of Todga-N-Dodecane Solvent With a Monoamide for High Loading of Lanthanides(III) and Actinides(III), Solvent Extraction and Ion Exchange, 2007. [cited by applicant]
Taylor, et al., Treatment of Human Contamination With Plutonium and Americium: Would Orally Administered Ca- or Zn-DTPA be effective? Radiation Protection Dosimetry, vol. 127, pp. 469-471, 2007. [cited by applicant]
Thompson, et al, Element 97, Physics Review, vol. 77, pp. 838, 1950. [cited by applicant]
Thompson, et al, Chemical properties of Berkelium, Journal of the American Chemical Society, vol. 72, pp. 2798-2801, 1950. [cited by applicant]
Trissel, L. et al., ASHP Handbook on Injectable Drugs 4th ed, pp. 622-630, 1986. [cited by applicant]
Turanov, et al., Synergistic Extraction of U(VI), Th(IV), and Lanthanides(III) from Nitric Acid Solutions Using Mixtures of Todga and Dinonylnaphthalene Sulfonic Acid, Solvent Extraction and Ion Exchange, 2018. [cited by applicant]
Umeda, et al., Separation of Americium from Plutonium-Solvent Extraction Raffinate by Extraction Chromatography using Todga Absorbent, Atlantate, 2004. [cited by applicant]
U.S. Food and Drug Administration, Guidance for Industry Calcium DTPA and Zinc DTPA Drug Products—Submitting a New Drug Application. 2004. [cited by applicant]
US. Food and Drug Administration, Guidance for Industry Internal Radioactive Contamination—Development of Decorporation Agents. 2006. [cited by applicant]
U.S. Food and Drug Administration, Guidance for Industry Product Development Under the Animal Rule 2015. [cited by applicant]
U.S. Food and Drug Administration, Approval of New Drugs When Human Efficacy Studies Are Not Ethical or Feasible. 2015, U.S. FDA: Washington, DC. [cited by applicant]
Van Der Ende, et al., Lanthanide ions as spectral converters for solar cells, Physical Chemistry Chemical Physics, vol. 11, pp. 11081-11095, 2009. [cited by applicant]
Van Wijngaarden, et al. Energy Transfer Mechanism for Downconversion in the (Pr3+, Yb3+) couple, Physics Review, vol. 81, Issue 15, pp. 155112, 2010. [cited by applicant]
Wadsworth, et al., Present Status of Cerium (IV)-Cerium (III) Potentials, Analytical Chemistry, vol. 29, pp. 1824-1825, 1957. [cited by applicant]
Wai, et al., Carboxylate-Derived Calixarenes With High Selectivity for Actinium-225, Chemical Communications pp. 377-378, 1998. [cited by applicant]
Wang, et al. Down- and Up-Conversion Photoluminescence, Cathodoluminescence and Paramagnetic Properties of NaGdF4 : Yb3+,Er3+ Submicron Disks Assembled From Primary nanocrystals, Journal of Materials Chemistry, Issue 16… [cited by applicant]
Wang, et al. Extraction of Trivalent Americium and Europium With Todga Homologs From HNO3 Solution, Journal of Radioanalytical and Nuclear Chemistry, vol. 313, pp. 309-318, 2017. [cited by applicant]
Wang, et al. Preparation of Core-Shell NaGdF4 Nanoparticles Doped with Luminescent Lanthanide Ions to be Used as Upconversion-Based Probes, Nature Protocols, vol. 9, No. 7, pp. 1634-1644, 2014. [cited by applicant]
Wawrzynczyk, et al. Ligand-dependent luminescence of ultra-small Eu3+-doped NaYF4 nanoparticles, Journal of Nanoparticle Research, vol. 15, pp. 1707, 2013. [cited by applicant]
Weidle et al., The Emerging Role of New Protein Scaffold-based Agents for Treatment of Cancer, Cancer Genomics and Proteomics. vol. 10, pp. 155, 2013. [cited by applicant]
Weitl, et al., Specific sequestering agents for the actinides. 3. Polycatecholate ligands derived from 2,3-dihydroxy-5-sulfobenzoyl conjugates of diaza- and tetraazaalkanes, Journal of the American Chemical Society, vol… [cited by applicant]
Welcher, F. J. The analytical uses of ethylenediamine tetraacetic acid; 1958. [cited by applicant]
Wermuth, C. et al., Designing Prodrugs and Bioprecursors, pp. 561-586, 2003. [cited by applicant]
Whitaker, et al., Applications of Diglycolamide Based Solvent Extraction Processes in Spent Nuclear Fuel Reprocessing, Part 1: Todga, Solvent Extraction and Ion Exchange, 2018. [cited by applicant]
Whitcomb, et al., A Public Health Perspective on the U.S. Response to the Fukushima radiological emergency. Health Phys, vol. 108, No. 3, pp. 357-363, 2015. [cited by applicant]
White, et al., Specific Sequestering Agents for the Actinides. 16. Synthesis and Initial Biological Testing of Polydentate Oxohydroxypyridinecarboxylate Ligands, Journal of Medicinal Chemistry , vol. 31, No. 1, pp. 11-1… [cited by applicant]
Wilden, A. et al. Unprecedented Inversion of Selectivity and Extraordinary Difference in the Complexation of Trivalent f-Elements by Diastereomers of a Methylated Diglycolamide, Chemistry a European Journal, 2019. [cited by applicant]
Xu, et al., Specific Sequestering Agents for the Actinides. 28. Synthesis and Initial Evaluation of Multidentate 4-Carbamoyl-3-hydroxy-1-methyl-2(1H)-pyridinone Ligands for in Vivo Plutonium (IV) Chelation, Journal of M… [cited by applicant]
Yantasee, et al., Novel Sorbents for Removal of Gadolinium-Based Contrast Agents in Sorbent Dialysis and Hemoperfusion: Preventive Approaches to Nephrogenic Systemic Fibrosis (NSF), Nanomedicine, vol. 6, No. 1, pp. 1-8,… [cited by applicant]
Ye, et al. Down conversion luminescence of Tb3+—Yb3+ codoped SrF2 precipitated glass ceramics, Journal of Non-Crystalline Solids, vol. 357, Issues 11-13, pp. 2268-2271, 2011. [cited by applicant]
Ye, et al. Enhanced cooperative quantum cutting in Tm3+—Yb3+ codoped glass ceramics containing LaF3nanocrystals, Optics Express, vol. 16, No. 12, pp. 8989-8994, 2008. [cited by applicant]
Zou, et al. Broadband Dye-Sensitized Upconversion of Near-Infrared Light, Nature Photonics, vol. 6, pp. 560-564, 2012. [cited by applicant]
Zhang et al, Novel enterobactin analogues as potential therapeutic chelating agents: Synthesis, thermodynamic and antioxidant studies Scientific Reports, vol. 6, pp. 1-12, 2016. [cited by applicant]
Zhu, et al. An active-core/active-shell structure with enhanced quantum-cutting luminescence in Pr—Yb co-doped monodisperse nanoparticles, Nanoscale, vol. 6, pp. 10500-10504, 2014. [cited by applicant]
Zhu, X et al. Cumulative study on solvent extraction of elements by N,N,N ,N-tetraoctyl-3-oxapentanediamide (Todga) from nitric acid into n-dodecane, Analytica Chimica Acta 527, pp. 163-168, 2004. [cited by applicant]
International Preliminary Report on Patentability dated Nov. 6, 2018 in International Patent Application No. PCT/US2017/030628. [cited by applicant]
International Preliminary Report on Patentability dated Mar. 12, 2019 in International Patent Application No. PCT/US2017/050121. [cited by applicant]
International Preliminary Report on Patentability dated Apr. 11, 2019 in International Patent Application No. PCT/US2017/048910. [cited by applicant]
International Preliminary Report on Patentability dated Apr. 11, 2019 in International Patent Application No. PCT/US2017/048934. [cited by applicant]
International Search Report and Written Opinion dated Jul. 27, 2017 in International Patent Application No. PCT/US2017/030628. [cited by applicant]
International Search Report and Written Opinion Dated Nov. 13, 2017 in International patent application PCT/US2017/050121. [cited by applicant]
International Search Report Dated Dec. 21, 2017 in International Patent Application No. PCT/US2017/048910. [cited by applicant]
International Search Report Dated May 11, 2018 in International Patent Application No. PCT/US2017/048934. [cited by applicant]
Office Action Dated Nov. 21, 2018 in U.S. Appl. No. 15/442,441. [cited by applicant]
Office Action Dated May 6, 2019 in U.S. Appl. No. 15/442,441. [cited by applicant]
Office Action Dated Aug. 23, 2019 in U.S. Appl. No. 15/442,441. [cited by applicant]
Supplementary European Search Report, Dated Nov. 15, 2019, in European Application No. EP 17793154. [cited by applicant]
Extended European Search Report Dated Mar. 24, 2020 in European App. No. 17849400.1. [cited by applicant]
Pharmaceutics, 1997, vol. 57 No. Suppl, pp. 62-63. [cited by applicant]
Decision to Grant in European Application No. 17849400.1, dated Oct. 7, 2022, in 2 pages. [cited by applicant]
Decision on Petition in U.S. Appl. No. 16/330,601, dated Jun. 23, 2022. [cited by applicant]
Office Action issued in European Application No. 17793154.0, dated Sep. 20, 2022, in 4 pages. [cited by applicant]
Decision of Refusal in Japanese Application No. 2018-557384, dated Sep. 29, 2022, with English translation, in 5 pages. [cited by applicant]
Corrected Notice of Allowability dated Nov. 28, 2022, in U.S. Appl. No. 16/330,601. [cited by applicant]
Notice of Allowance dated Nov. 7, 2022, in U.S. Appl. No. 16/330,601. [cited by applicant]
Carter et al., Developing scandium and yttrium coordination chemistry to advance theranostic radiopharmaceuticals, Communications Therapy, https://doi.org/10.1038/s42004-020-0307-0, pp. 1-7 (2020). [cited by applicant]
Notice of Allowance dated Jan. 30, 2023, in U.S. Appl. No. 16/365,132. [cited by applicant]
Office Action dated Jan. 31, 2023, in Japanese Application No. 2022-008581. [cited by applicant]
Corrected Notice of Allowability dated May 19, 2023, in U.S. Appl. No. 16/330,601. [cited by applicant]
Notice of Allowance dated May 24, 2023, in U.S. Appl. No. 16/365,132. [cited by applicant]
Office Action in Japanese Application No. 2022-008581, dated Jun. 27, 2023, in 5 pages. [cited by applicant]
Corrected Notice of Allowability in U.S. Appl. No. 16/365,132, dated Mar. 21, 2023. [cited by applicant]
Notice of Allowance in Japanese Application No. 2019-516989, dated Mar. 29, 2023. [cited by applicant]
Non-Final Office Action dated Mar. 30, 2023, in U.S. Appl. No. 16/097,782. [cited by applicant]
Corrected Notice of Allowability dated Apr. 12, 2023, in U.S. Appl. No. 16/330,601. [cited by applicant]
Notice of Allowance dated Jun. 28, 2023, in U.S. Appl. No. 16/365,132. [cited by applicant]
Office Action in Canadian Application No. 3,022,852, dated Jun. 22, 2023, in 6 pages. [cited by applicant]
Notice of Allowance dated Jan. 8, 2024 in U.S. Appl. No. 16/365,132, in 12 pages. [cited by applicant]
Final Office Action dated Aug. 1, 2023, in U.S. Appl. No. 16/097,782. [cited by applicant]
Intention to Grant dated May 30, 2023, in European application No. 17873523.9. [cited by applicant]
Notice of Allowance in Japanese Application No. 2022-8581, dated Oct. 16, 2023. [cited by applicant]
Office Action in Canadian Application No. 3,035,966, dated Oct. 23, 2023. [cited by applicant]
Office Action in Canadian Application No. 3,038,723, dated Oct. 27, 2023. [cited by applicant]
Decision to Grant in European Application No. 17793154.0, dated Nov. 2, 2023. [cited by applicant]
Office Action in Canadian Application No. 3,038,670, dated Nov. 1, 2023. [cited by applicant]
(Office Action: Final Rejection) in U.S. Appl. No. 16/097,782, dated Jan. 12, 2024, in 11 pages. [cited by applicant]
Office Action in Canadian application No. 3,022,852, dated Jan. 16, 2024, in 6 pages. [cited by applicant]
Rees et al., “Evaluating the potential of chelation therapy to prevent and treat gadolinium deposition from MRI contrast agents”, Scientific Reports, published online Mar. 13, 2018, www.nature.com/scientificreports, in … [cited by applicant]
Office Action Dated Jan. 19, 2022 in U.S. Appl. No. 16/097,782. [cited by applicant]
Notice of Allowance dated Nov. 26, 2021 in Japanese Patent Application No. 2019-512761. [cited by applicant]
Notice of Allowance dated Oct. 29, 2021 in U.S. Appl. No. 16/330,601. [cited by applicant]
Supplemental Notice of Allowability dated Dec. 14, 2021 in U.S. Appl. No. 16/330,601. [cited by applicant]
Notice of Allowance dated Mar. 16, 2022 in U.S. Appl. No. 16/330,601. [cited by applicant]
Notice of Allowance dated Jul. 27, 2022 in U.S. Appl. No. 16/330,601. [cited by applicant]
Notice of Reason for Rejection dated Mar. 10, 2022 in Japanese Patent Application No. 2018-557384. [cited by applicant]
Intention to Grant dated May 18, 2022, in European Application No. 17849400.1. [cited by applicant]
Non-Final Office Action dated Feb. 25, 2022, in U.S. Appl. No. 16/365,132. [cited by applicant]
Office Action with English translation in Japanese Application No. 2019-516989, dated Aug. 5, 2022. [cited by applicant]
Corrected Notice of Allowability in U.S. Appl. No. 16/365,132, dated Mar. 26, 2024, in 3 pages. [cited by applicant]
Advisory Action in U.S. Appl. No. 16/097,782, dated Apr. 19, 2024, in 3 pages. [cited by applicant]
Corrected Notice of Allowability in U.S. Appl. No. 16/365,132, dated May 2, 2024, in 4 pages. [cited by applicant]
Interview Summary in U.S. Appl. No. 16/097,782, dated Apr. 15, 2024, in 3 pages. [cited by applicant]
Corrected Notice of Allowability in U.S. Appl. No. 17/665,135, dated Jun. 28, 2024, in 3 pages. [cited by applicant]
Notice of Allowance in U.S. Appl. No. 16/365,132, dated Mar. 1, 2024, in 3 pages. [cited by applicant]
Office Action in Japanese application No. 2023-16016, dated Mar. 5, 2024, in 3 pages. [cited by applicant]
Extended European Search report in European Application No. 23204493.3, dated Feb. 16, 2024, in 10 pages. [cited by applicant]
Notice of Allowance in U.S. Appl. No. 17/665,135, dated Jun. 20, 2024, in 47 pages. [cited by applicant]